Mylan in India

Mylan’s journey in India started with the acquisition of Matrix Laboratories Limited in 2007. Matrix was renamed as Mylan Laboratories Limited in 2011. Today, Mylan has established a formidable footprint in India in terms of its finished dosage formulations (FDF) manufacturing capabilities, providing high quality medicine to patients around the world. A vertically integrated operating structure, through our large active pharmaceutical ingredient (API) manufacturing capability has enabled a number of drug master filings (DMFs) with multiple regulatory authorities across the globe.

With the acquisition of Agila Specialties in 2013, Mylan significantly expanded and strengthened its global injectable platform by adding six additional injectable facilities in India and providing Mylan’s entry into new high-growth geographic markets.

Our state-of-the-art Research & Development (R&D) facilities for API & FDF are located at Hyderabad and for Injectables at Bengaluru. These facilities have more than 1000 scientists, providing end-to-end pharmaceutical services. 

Mylan India also houses a Biologics R&D Laboratory involved in complex-analytic research primarily focusing on oncology and autoimmune disease and expects to begin launching products from 2015.

Mylan started commercial operations in India in August 2012 with an innovative range of ARVs used in the treatment of HIV/AIDS in adults and children, further expanding to include women’s care, oncology and critical care. Our sales force of more than 400 representatives, work closely with health care professionals to create access in India for Mylan’s high-quality, innovative medicines across the country.  

Mylan India also houses a Biologics R&D Laboratory involved in complex-analytic research primarily focusing on oncology and autoimmune disease and expects to begin launching products from 2015.

Mylan India comprises of nearly 50% of Mylan’s global workforce. 

Leadership

  • Questions?

    Get more information on our products, services and Mylan Global Center locations.

    Contact us

  • Business Opportunities

    Do you have an opportunity or a collaboration idea?

    Partner with us

  • Mr. Rakesh Bamzai

    Rakesh Bamzai_

    Managing Director & CEO  of Mylan Laboratories Limited, based in Bangalore, India. 

    Mr. Bamzai has over 20 years of experience in the Indian and global biopharmaceutical industry and is responsible for growing Mylan’s ARV, Active Pharmaceutical Ingredient (API), generic and specialty businesses in India and Emerging Markets.

    Through his career, Rakesh has played a significant role in building global biopharmaceutical business, with overall responsibility for APIs, finished dosage forms and biologics. Over the years, he spearheaded a number of strategic partnerships, to enable wider global access and market penetration for businesses. He has also led forays into branded formulations resulting in many successful brands, across therapies, in India and emerging markets.

    Rakesh graduated in Chemical Technology from UDCT, The University of Mumbai.”

  • Dr. Haribabu Bodepudi

    Dr. Hari Babu
    Head of Global Oral Solid Dose (OSD) and Active Pharmaceutical Ingredients (API) Operations
    Dr. Haribabu Bodepudi is the Head of Global Oral Solid Dose (OSD) and Active Pharmaceutical Ingredients (API) Operations in Mylan, Based in Hyderabad, India.

    Dr. Bodepudi has over 21 years of Pharma experience in various functions, at senior levels of responsibility, including R&D, manufacturing, regulatory and quality. His current responsibility as head of Mylan’s global OSD & API operations encompasses the managing and effective utilization of manufacturing capacity, to produce products that reach 7 billion people with a growing demand for high quality, affordable and accessible healthcare solutions. Prior to taking over as head of global  OSD & API, Dr. Bodepudi was the Managing Director & CEO of Mylan Laboratories Limited.


    Dr. Bodepudi did his Ph.D. from Andhra University and has a number of national and international publications to his credit. He also filed for several patents during his tenure in the industry.

  • Mr. Sanjeev Sethi

    Head of Global Injectable Operations


    Mr. Sanjeev Sethi is the Head of Global Injectable Operations in Mylan, based in Bangalore, India.

    Sanjeev Sethi has over 25 years of experience in the pharmaceutical industry. He joined the organisation in 2005 and assumed responsibility for the Technical Operations of Finished Dosage Forms at the erstwhile Matrix Laboratories, as Senior Vice President and was soon elevated to Executive Vice President. Sanjeev played a vital role in building the teams and infrastructure for R&D, Regulatory Affairs, Quality Management and Commercial Manufacturing of Finished Dosage Forms. Under his leadership, several products were developed and commercialised, including the flagship portfolio of ARV finished dosage forms. Prior to taking over his current position Mr. Sethi was Mylan’s global head of Scientific Affairs, in which capacity he led the portfolio management, R&D, regulatory affairs and launch management for the organisation.

    Previously he had stints at major pharmaceutical companies including Ranbaxy and Sandoz in the areas of Formulations Development and Regulatory Affairs.

    Sanjeev has a post graduate degree in pharmaceutical sciences from Punjab University and has 40 international patents to his credit.